DCOY Overview

Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

Wall Street analysts forecast DCOY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCOY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Decoy Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Decoy Therapeutics Inc. EPS for the last quarter amounts to -305.75 USD, increased 67.63

Decoy Therapeutics Inc (DCOY) has 11 emplpoyees as of April 22 2026.

Today DCOY has the market capitalization of 3.13M USD.